Duncan Ross, Ph.D.

Duncan Ross, PhD

Duncan Ross, Ph.D.
Global Stem Cells Group Advisory Board member

Duncan Ross, Ph.D., is a graduate of the University of Miami Immunology and Biochemistry departments where he specialized in stem cell transplantation and protein expression and purification.

Dr. Ross has been featured in various peer reviewed publications including “Blood and the Biology of Blood.” and “Marrow Transplantation,” in which he discussed the use of various cell types to suppress immunological diseases.

Dr. Ross heads Kimera Labs and is a board member of the federal nonprofit research organization the Kimera Society. Dr Ross is an expert in stem cell culture and  has developed and patented proprietary methods of stem cell manipulation and licensing using growth factors and nucleic acids.

Joseph Purita, M.D.

Buenos Aires Stem Cell Symposium

Joseph Purita, M.D.
Global Stem Cells Group Advisory Board member

Joseph Purita, M.D., is a world-renowned orthopedic surgeon and stem cell pioneer, using cutting edge technology in regenerative medicine in conjunction with stem cell platelet rich plasma (PRP) therapy to treat orthopedic injuries and relieve pain. He is also a pioneer in the use of the laser in orthopedic surgery.

Named a U.S. News and World Report Top Doctor in 2012, Dr. Purita, a renown orthopedic and arthroscopic surgeon, heads Global Stem Cells Group’s Scientific Advisory Board. A pioneer in the use of stem cell and PRP therapy for orthopedic conditions, Dr. Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.

Dr. Purita is the director of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, specializing in the use of stem cells and PRP injections for use in sports medicine and other musculoskeletal conditions. The Institute has treated some of the most prominent professional athletes from all major sports in both the U.S.. and abroad.

He is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals,

Dr. Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.

He is Is Board Certified By The Following Organizations:
•  American Board of Orthopedic Surgery
•  American College of Orthopaedic Surgery
•  American Board of Pain Management

Dr. Purita is a popular speaker at regenerative and orthopedic conferences worldwide.

 

 

 

 

 

stem cell training course in Barcelona

Global Stem Cells Group and its subsidiary Stem Cell Training, Inc., have announced plans to hold a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Orthopedic and cosmetic surgeon J. Victor Garcia Gimenez, M.D. will conduct the course for qualified physicians and medical professionals.

stem cell training course in Barcelona

J. Victor Garcia Gimenez, M.D.

MIAMI, Aug. 10, 2016–Global Stem Cells Group and its subsidiary Stem Cell Training, Inc. will host a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Victor Garcia Gimenez, M.D. will conduct the two-day, intensive, hands-on “Adipose-derived Harvesting, Isolation and Re-integration Training Course” for physicians and qualified medical professionals.

Garcia Gimenez, a member of the Global Stem Cells Group Advisory Board, first conducted the course for GSCG in 2014. The

course is part of the Miami-based biotech company’s growth in the European market.

The training course was developed for physicians and high-level practitioners to learn clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. Stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving treatment. Patients experience an effective, non-invasive procedure, and a faster recovery period with little to no downtime.

Garcia Gimenez is a specialist in orthopedic and cosmetic surgery, president of Therapeutic Confrontations (CONFTERA), and practices cosmetic and anti-aging medicine, as well as aesthetic therapies in Barcelona. He is the president of the Spanish Society of Medicine and Cosmetic Surgery; co-director of the UAB-SEMCC; Chairman for Spain of the International Academy of Cosmetic Surgery, in addition to other medical and professional boards.

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:stem cell training course in Barcelona

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

stem cell training course in BarcelonaStem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatment.

To view this press release live online, click here.

###

stem cell training

(Pictured: bone marrow stem cells)

Global Stem Cells Group will host a stem cell training course in SVF and bone marrow aspiration techniques July 28-29, 2016.

MIAMI, July 28, 2016–Global Stem Cells Group, in collaboration with South Korean biomedical company N-Biotek will host a course in stromal vascular fraction (SVF) and bone marrow aspiration techniques for physicians at the N-Biotek headquarters in Gyeonggi-do Province of South Korea July 29 and 29, 2016.

The training course is part of a collaborative agreement between GSCG’s Adimarket division and N-Biotek, a worldwide stem cell trainingbiomedical and lab equipment manufacturer, to promote and distribute their stem cell technology equipment throughout Latin America.

The two-day, hands-on training covers the latest technology and procedures in SVF and bone marrow stem cell techniques. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The SVF and bone marrow aspiration course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training teach effective, in-office regenerative medicine techniques.

stem cell trainingN-Biotek develops a range of custom lab products including the Esfomi cosmetic line, and the Stem Cell Total Solution for emerging stem cell businesses.

N-Biotek is the only company that builds the whole stem cell processing system for partners ready to begin work in the stem cell industry. N-Biotek meets every need for stem cell clinicians, including biological clean room construction, equipment installation and stem cell processing consulting.

N-Biotek currently distributes medical equipment and services to facilities and professionals in more than 100 countries.
For more information, visit the Global Stem Cells Group website, email bnovas@stemcellsgroup(dot)com, or call +1 305 560 5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cellGlobal Stem Cells Group research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About N-Biotek:

N-Biotek, Inc., founded in 2000 and located in the Gyeonggi-do Province of South Korea, is a leading manufacturer and supplier of bio-technology-related laboratory equipment. N-Biotek delivers high quality biomedical equipment to more than 100 countries.

To view this press release live online, click here

###

STEM CELL RESEARCH GUIDELINES

Stem cell research has never been more advanced, and as a result many different types of treatments are currently offered on the market. Unfortunate

ly, some providers are practicing quackery in stem cell therapies, and an abundance of well-intentioned scientific and medical personnel are prematurely publicizing their work. These providers and publishers have cast an unfair shadow of mistrust on this very important branch of medical research and potential treatments.

On the other hand, the contributions of professional medical and stem cell societies and other organizations require self-regulation through accreditation and certification, development of standards, and creation of a platform for collaboration among stakeholders.

Professional Guidelines for responsible Stem Cell Research

guidelines for stem cellInternational Society for Stem Cell Research (ISSCR) is the largest professional organization of stem cell scientists. In 2007, ISSCR impaneled a broad international taskforce to develop a set of professional guidelines for responsible translational stem cell research. Their principles include high standards of preclinical evidence, peer review, scrupulous review of clinical protocol by an Institutional Review Board (IRB), rigorous informed consent, and publication of results whether positive or negative.

The general scientific consensus is that most stem cell therapies are not ready for marketing or commercialization. But the industries that are providing these treatments are increasingly sophisticated and organized, and are challenging established regulatory frameworks.

The International Society for Cellular Therapy (ISCT) has an interest in the promotion of stem cell research and development, but it also is interested in a broader range of cell-based interventions such as immune cell interventions, reproductive medicine, and gene therapy. The ISCT taskforce has working groups on definitions, scientific evidence and biological rationale, laboratory cell processing, clinical practice, regulation, commercial implications, communications, and policy.

Develop terminology, define levels of scientific evidence in new guidelines for stem cell research

The key goals are to develop an appropriate terminology, define the levels of scientific evidence needed to justify routine use or commercialization of a stem cell therapy, address questions of “experimental” and “innovative” use, and understand the global regulatory landscape in order to identify gaps and contradictions.

The ISSCR published revised guidelines for research and clinical translation involving stem cells on May 12, 2016. These new guidelines update and combine guidelines on stem cell research and clinical translation previously issued in 2006 and 2008 Jonathan Kimmelman, Associate Professor of Biomedical Ethics at McGill University, chaired the ISSCR Guidelines Update Task Force. The task force was made up of 25 experts in basic research, clinical research, and bioethics, and received feedback from 85 external individuals and organizations.

2016  guidelines: covering new ground in stem cell research

The 2016 guidelines cover new ground in areas such as gene editing and induced pluripotent stem cells. They introduce a new focus on the communication of results. The task force recognizes that results and potential applications can be exaggerated, leading to distorted understandings of research outcomes in the scientific community, popular press, and among potential patients. The “14-day rule” limiting experimentation on human embryos or embryo-like structures is upheld in these guidelines, although one task-force member has suggested that this may soon be open to revision.

In May, 2016 ISSCR released the following list of all of the new topics addressed in the revised guidelines as part of the announcement of its report:

  • Define an Embryo Research Oversight (EMRO) process to encompass both human embryonic stem cell research and human embryo research that may not explicitly pertain to stem cells or generating new stem cell lines;
  • Exclude the generation of induced pluripotent stem cells (iPS cells) from specific stem cell research oversight, and instead call on the existing human subjects review processes to oversee donor cell recruitment (iPS cells behave like embryonic stem cells but are derived by reprogramming more differentiated tissue cells);
  • Support laboratory-based research that entails gene editing of the nuclear genomes of human sperm, egg, or embryos, when performed under rigorous review, but hold that any attempt to apply this clinically would be premature and should be prohibited at this time;
  • Define principles for evaluating both basic and clinically applied research on mitochondrial replacement therapy, in concordance with recent deliberations in the U.K., U.S., and elsewhere;
  • Determine that where there is no undue financial inducement to participate, it may be acceptable to compensate women who donate eggs for research;
  • Recognize that the development of increasingly complex in vitro models of early stages of human development should undergo specialized review;
  • Highlight opportunities to strengthen preclinical studies in stem cell research, including reproducibility and stringent standards for experimental design;
  • Call for robust standards for preclinical and clinical research evidence as clinical trials progress and rigorous evaluation for safety and efficacy before marketing approval;
  • Address the valuable contributions made by patients or patient groups to support clinical research and a framework to ensure this is achieved without compromising the integrity of the research;
  • Highlight the responsibility of all groups communicating stem cell science and medicine—scientists, clinicians, industry, science communicators, and media—to present accurate, balanced reports of progress and setbacks.

The good news is that stem cell research is evolving into a highly respected and in-demand branch of healing that many Global Stem Cells Groupconsider to be the future of medicine. Since pluripotent stem cells have the ability to differentiate into any type of cell, they are used in the development of medical treatments for a wide range of conditions including physical trauma, degenerative conditions, and genetic diseases (in combination with gene therapy). Further treatments using stem cells are being developed due to stem cells’ ability to repair extensive tissue damage.

Great levels of success and potential have been achieved from research using adult stem cells. In early 2009, the FDA approved the first human clinical trials using embryonic stem cells. Embryonic stem cells are pluripotent, which means they can become any cell type of the body, with the exception of placental cells. More and more is being discovered about the plasticity of adult stem cells, increasing the potential number of cell types an adult stem cell can become.

###

stem cell treatment, stem cells, medical tourism, regenerative medicine

Global Stem Cells Group announces the launch of two new stem cell treatment clinics in the cities of Arica and Iquique in northern Chile. The facilities are part of the international biotech company’s expanding presence in Latin America.

MIAMI, May 31, 2016—Global Stem Cells Group, a leading international biotechnology company, announces the launch of operations at two new GSCG clinics in the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expanding presence in Latin America.

Both the Arica and Iquique clinics offer the most advanced protocols and techniques in stem cell medicine to patients from around the world.

stem cell treatment, medical tourism, stem cells, regenerative medicine

The clinics are headed by stem cell specialists Victor Perez, M.D., and Duval Aguirre, M.D., and will offer treatments in chronic degenerative conditions, Type 2 diabetes, COPD, traumatology and sports medicine.

Global Stem Cells Group, has been expanding its clinical presence throughout Latin America and worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics. The new Arica and Iquique clinics are certified for the medical tourism market.

Global Stem Cells Group is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.

About the Global Stem Cells Group:

GSCG2

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

To view this press release live online, click here

###

 

adimarket, Progenikine™ SVF Closed System, stem cell treatmentsm regenerative medicine

Global Stem Cells Group subsidiary Adimarket is preparing to launch Progenikine™, a new SVF closed system kit utilizing EmCyte technology, containing all the elements necessary to process adipose tissue and obtain stromal vascular fraction in a sterile environment.

Progenekine™, stem cells, stem cell ttreatment, stem cell research, medical tourism, regenerative medicine

MIAMI, May 31—Adimarket, a subsidiary of Global Stem Cells Group, Inc. is preparing to launch Progenikine™, its new and approved SVF closed system kit using EmCyte technology, and is expected to be available to physicians in July, 2016. The Progenikine kit contains all the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.

Adipose derived stem cells (ASCs) are used by physicians for a variety of indications. Most commonly, ASCs are isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity of the clinical procedure, and comply with Adimarket, Progenikine™ SVF Closed System, stem cell treatments, regenerative medicineregulatory requirements.

Developed in conjunction with Patrick Pennie, Emcyte CEO, and Maritza Novas Director of Research and Development for Global Stem Cells Group, Progenikine fuses elements from Emcyte systems with the Global Stem cells Group SVF protocols. The kit can provide a low cost, rapid and

simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.

“We’re excited to launch the Progenikine kit, the newest product designed to help Global Stem Cells Group’s fulfill its m

ission to provide accessible products to our member clients,” says Benito Novas, CEO of Global Stem Cells Group. “These are the milestones that bring us closer to ensuring that more patients will be able to gain access to stem cell therapies.”

To learn more about the Progenikine kit, visit the Global Stem Cells Group website, email bnovas@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About Emcyte:

stem cells, progenekine™, medical tourism, stem cell treatments, adipose stem cells

Fort Myers, Florida-based EmCyte Corporation is a leader in autologous cellular biologics with the GenesisCS Component Concentrating Systems. These systems provide patients with the best opportunity for rapid recovery an

d provide practitioners with the most advanced clinical point of care experience. EmCyte systems are developed to meet every clinical requirement, giving the physician better clinical choices. EmCyte devices have been independently reviewed and show to produce buffycoat concentrations of 6x to greater than 10x baseline in 7mLs, with yields ranging from 70 percent to greater than 90 percent

EmCyte technology allows for the safe extraction of concentrated platelets and other regenerative cell types from the patient’s own blood. These cells are then re-suspended in a small volume of the patient’s blood plasma and then applied to the treatment site.

To view this release live online, click here

###

stem cells

In October, 2014, legendary hockey player Gordie Howe, then 86, was on death’s door after suffering a debilitating acute hemorrhagic, left thalamus stroke. Upon returning home from the hospital, Howe needed someone to lift him from his bed to a wheelchair and back. He couldn’t remember the names of his four children, Marty, Mark, Cathy, and Murray, and his condition continued to grow worse in subsequent weeks. According to an article in New York Magazine, when Mark took his father to get an epidural to relieve his back pain, the attending physician took one look at Gordie and asked Mark if it might be better to just let his father go. On the rare occasion when Gordie did manage to speak, he would tell his children, “Just take me out back and shoot me.”

The man for whom the term “hat trick” was coined, Howe retired from hockey at age 52 after four decades of professional play, having scored more goals than any other NHL player.  But over the past 10 years, his health declined dramatically—heart disease, dementia, and spinal stenosis—despite his family’s and physician’s best efforts to find medical solutions. After his stroke, Keith Olbermann aired a preemptive obituary on ESPN. The family made funeral plans. Murray, his youngest son, wrote a eulogy.

Experimental stem cell treatment

Around Thanksgiving, 2015, Howe’s family learned about an experimental stem cell treatment that could save his life. The plan was to inject up to 100 million neural stem cells into his spinal column in the hopes that the stem cells would migrate to his brain and help his body repair itself. Howe could improve within 24 hours, and receive the treatment anytime—just not in the United States. The procedure wasn’t FDA-approved, and Howe would have to receive the treatment at a clinic in Tijuana.

Howe’s son Murray, a radiologist, looked into the treatment and thought it was promising. The real concern was transporting the immobile Howe to Mexico. Daughter Cathy worried that he might die during the treatment, but Mark responded bluntly: “If he does die, what’s the difference? He’s going to be gone soon no matter what.”

While the family weighed the stem cell treatment idea, Howe was admitted to the hospital with severe dehydration, caused by his unwillingness to swallow. When he returned home, he still had no use of his right side, and the family assumed he would never walk again. The Howe children decided to give the stem cell treatments a try.

Two days later, the Howes flew their Dad to San Diego. In the air, Gordie grew agitated and got the attention of a flight attendant, who spent 10 minutes kneeling by his seat trying to understand something he wanted to tell her. Due to his profound memory loss, Howe didn’t know he had suffered a stroke, why he was on a plane, or where he was going. But he remembered one thing, which he managed to whisper to the fight attendant: “I was a pro hockey player.”

The next morning, Marty and Murray drove with their father across the border to Clínica Santa Clarita, where Gordie bent over a table to expose his lower back so that a needle could be inserted into his spinal canal to inject the stem cells. Howe was given two types of stem cells – neural stem cells and mesenchymal stem cells. The second type, derived from bone marrow, has anti-inflammatory properties and secretes chemicals that promote healing.

The procedure then required Howe to lie prone for eight hours. After the eight hours passed, Gordie told Murray he needed to use the bathroom and that he intended to walk there in order to do so. Since the stroke, Gordie had only managed to walk one time—10 steps, with a walker. Murray reminded his Dad that he couldn’t walk.

Recovery milestone after stem cell treatment

Howe stood up, and with Murray’s support, walked for the first time in more than a month—to the bathroom. This milestone became an oft-repeated story among the Howe family, and Gordie’s revival became an irresistible story for the sports pages. Back home, Gordie returned to something resembling the normal life of an 86-year-old. He pushed the grocery cart, helped with the dishes, and could go fishing so long as one of his sons reminded him that a tug on the line meant he needed to start reeling. The family released a video of Gordie standing stationary, firing a puck, five-hole, past his 8-year-old great-grandson. Keith Olbermann apologized for his premature obituary.

Howe’s children now had to figure out how to share his apparent recovery—a debate that proved just as contentious as their decision to fly him to Mexico for the treatment in the first place—with the world. Both Marty and Mark had played in the NHL alongside their father, but now Murray, the doctor, was giving interviews in his hospital scrubs, endorsing his father’s place in medical “miracle” history. He began referring to the stem-cell treatment as the “Gordie Howe Protocol,” and said that his Toledo-based hospital was looking into conducting an FDA-approved study of the procedure. In one interview, Murray Howe stated that “stem cells are the most promising thing in medicine since the discovery of antibiotics.”

As the story spread, the medical community started to question just how miraculous Howe’s recovery had been.

“Companies selling these products are preying on desperate and vulnerable people and exploiting their hope, much like snake-oil salesmen have done throughout most of human history,” wrote Judy Illes and Fabio Rossi, stem-cell experts at the University of British Columbia, in the Vancouver Sun. Even advocates pointed out that, though the field holds great promise, no reputable studies have shown that such a procedure should work.

And yet, for the children of ailing parents, such skepticism doesn’t matter. Murray’s response to one skeptic was, “What would you do for your father?”

Gordie Howe’s therapy would cost an average patient about $30,000.

Athletes, whether playing or retired, have a special need for the regenerative capacity that stem cells are believed to provide. Athletes break bones, strain ligaments, bash knees and wear out cartilage. If stem cells’ restorative capability is proven, they could be considered the latest form of sports medicine.

Since Howe’s treatment in late 2014, two other athletic legends have received stem cell treatments—former quarterbacks Bart Starr and John Brodie. And the rest of the population, particularly aging baby boomers, isn’t far behind.

stemcellgroupStill, while acceptance of stem cell therapy has grown, so have controversies surrounding its use. While clinical trials authorized by the U.S. Food and Drug Administration are rapidly expanding in the U.S., so are treatments outside the regulated system. Patients are going to stem cell clinics in other countries that approve stem cell therapies.

For its part, the FDA is drafting guidelines, although the U.S. and Canada still trail other countries in approving stem cell treatments.

Last year, the FDA issued draft guidelines to clarify what types of human cell therapy it regulates. The short answer: Most of them, with “limited exceptions,” according to an FDA email sent in response to questions from The San Diego Union-Tribune. These exceptions include cells or tissues that are “minimally manipulated,” not given with any other product and perform the same function in the donor as in the recipient.

All other stem cell therapies are seen as involving human cells, tissues and cellular and tissue-based products – also known as HCT/Ps – regulated by the FDA’s Center for Biologics Evaluation and Research.

“We understand that determining the appropriate regulatory path for HCT/Ps can be challenging, and the FDA is working diligently to develop guidance to help sponsors and physicians understand how to apply federal regulations to this complex and emerging field,” the agency said.

In January 2015, University of California, Davis stem cell researcher and blogger Paul Knoepfler estimated that more than 100 unauthorized stem cell clinics were operating in the United States. Later that year, he increased that estimate to up to 200.

Then on May 6, he wrote in his blog: “We are seeing a flood of professional athletes getting stem cell treatments in the past few years.”

Athletes and others who want these treatments bristle at what they call cumbersome, time-consuming regulations in the U.S. The situation can be urgent for seriously ill patients.

While it hasn’t been proven that the stem cells enabled his recovery, by all indications Gordie Howe’s health has improved significantly since receiving stem cell treatments. In November, 2015, Murray Howe said that his father’s physicians in the U.S. recommended hospice care in the weeks after the stroke, and the family was told he wouldn’t last more than two or three weeks,

“Then, suddenly, he is raking and sweeping and goofing around in the back yard,” Murray said.

 ###

 

 

###

Sources: The San Diego Union-Tribune, New York Magazine

MIAMI, April 30, 2016–Global Stem Cells Group CEO Benito Novas announced that the University of Santiago has become the latest GSCG affiliate to apply for Regenerative Technologies Alliance (RTA) certification. RTA certification represents the highest standards of excellence in current medical and laboratory practices against established standards.

The announcement comes less than a week after Global Stem Cells Group announced a mutual endorsement for an Asian-Pacific alliance with the university to host a regenerative medicine and stem cell symposium July 1-2 at the GSCG2university’s Santiago campus. Through the alliance, the two organizations have established a working agenda for collaborative initiatives and educational programs in stem cell and regenerative medicine research and development for 2016 – 2020.

Experts in the field of regenerative and cell-based medicine conduct the RTA certification program. The Regenerative Technologies Alliance, a 501(c)3 non-profit organization operated by Regenetech and supported by individuals and institutions committed to bringing peer oversight and transparency to the regenerative and cell-based medicine industry, provides certification for:

  • Laboratory Facilities that provide the processing of human tissue for the development of cell-based applications
  • Clinical facilities seeking to participate in authorized studies that are approved by Institutional Review Boards (IRB)
  • Medical facilities providing cell-based medical therapies to patients.

Regenetech RTA certificationAccording to Benito Novas, CEO of Global Stem Cells Group, the certification process will be conducted under the direction of David B. Audley, RTA Chair and General Secretary. Audley is a highly regarded medical marketing and management services consultant who co-founded MedTourGlobal after 10 years in the emerging field of regenerative medicine.

Santiago was the city chosen for the first RTA accreditation in Latin America. This type of accreditation differs from traditional accreditation processes in that it examines all aspects of service and patient care, considers the progress of the location and the potential for receiving international patients, as well as meeting quality expectations.

The alliance between Global Stem Cells Group and the University of Santiago extended an invitation to Audley and started the RTA application and review process to assess the reception, harvesting, bio-processing and application of stem cells, in the university’s Biotechnology and Molecular Biology Laboratory and Providencia Stem Cells Center. This international certification opportunity includes evaluating and reinforcing physicians working in those areas, and validating the processes and bio-technological resources against international standards.

RTA delegates are expected to visit the University of Santiago facility in July to conduct a physical inspection of the premises. The goal is to create a cell therapy hub in Santiago that can accommodate the needs of patients in neighboring countries seeking stem cell and regenerative medicine treatments. Strong patient demand in the United States and Europe have also created a growing interest in the medical tourism industry.

Global Stem Cells Group Chief Medical Officer Enrique Testart, M.D., heads a medical and scientific team tasked with establishing a new edition of the post-graduate diploma program, “Diplomat in Cell Therapy and Tissue Engineering” at Santiago University.
The theoretical and practical, 120-hour program will deliver the fundamentals of the most advanced cell therapies and clinical applications currently practiced safely and effectively in more than 35 cities worldwide.

Testart and Novas have collaborated on the push to highlight Chile’s appeal as a destination for patients seeking stem cell therapies for a variety of conditions, and as part of GSCG’s ongoing commitment to expand the reach of stem cell treatments throughout Latin America. Global Stem Cells Group’s Quito, Chile clinical facility is also in the process of earning RTA certification.

Novas says that GSCG aims to have all the company’s clinical facilities earn RTA certification by the end of 2016.

Global Stem Cells Group’s presence in Chile represents one of the largest integrated science and technology organizations associated with tissue engineering and tissue regeneration. GSCG represents the areas of research, development, medical appliances, equipment and protocols for clinical standards, and is fast becoming a global leader in adult stem cell therapies, medical training in stem cell protocols, and the manufacture of high quality products and supplies in regenerative medicine.

Their strategic leadership puts them in the forefront of stem cell research, medical education and patient care. Global Stem Cells Group comprises six companies, each of which works in specialty areas related to the stem cell industry .

To learn more, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

###

To view this press release live online, click here

cell assisted fat transfer

MIAMI, April 30, 2016–Global Stem Cells Group and Stem Cell Training, Inc. have announced the addition of a cell assisted fat transfer training course, to be conducted by Alfredo Hoyos, M.D., head of the GSCG Advisory Board, and Enrique Testart, M.D., GSCG Chief Medical Officer.

Two courses are scheduled, one to be conducted in Santiago, Chile August 23-24, and the other in Cancun, Mexico October 11-12.

The training course involves facial fat transfer injection combined with adipose-derived stem cells, to address the primary issues that concern patients in the aesthetic field, including facial aging caused by volume loss.

Hoyos is a plastic surgeon and stem cell expert who founded Stemlab, a Bogota, Colombia facility that conducts extensive research in regenerative medicine in an effort to establish stem cell treatments that can repair damaged tissue in living organisms.

Alfredo Hoyos, MD

Alfredo Hoyos, MD

Stemlab works to further the development of aesthetic techniques using stromal stem cells derived from adipose tissue. Hoyos is the inventor of high definition liposculpture (HDL) and dynamic definition lipoplasty (4D) techniques as well as other advanced techniques that focus on body contouring.

Testart is a surgeon specializing in child trauma microsurgery. He is also a medical entrepreneur and founder of Consortia Innovas S.A. in Santiago, Chile, an organization dedicated to consulting and clinical health management for clinical management firms and research and development-oriented planners on the latest treatments in regenerative medicine as they become available.

stem cells, stem cell research, stem cells Santiago Chile

Enrique Testart, MD

Hoyos and Testart will train qualified physicians on cell assisted fat transfer techniques and protocols, during which fat cells are harvested from the patient’s own body and redistributed to other areas of the body to augment sunken or thin regions of the face or body in order to add volume where it is desired.

Lipoinjection for cosmetic treatments can be unpredictable, and has a low rate of graft survival due to partial necrosis. To overcome these problems, cell assisted fat transfer (lipostransfer) was developed as a strategy wherein autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection. A stromal vascular fraction (SVF) containing ASCs is freshly isolated from half of the aspirated fat and recombined with the other half. This process converts relatively ASC-poor aspirated fat to ASC-rich fat, reducing postoperative atrophy of injected fat to a minimal leveGSCG2l that clinical trials have found does not change substantially after 2 months. Patients walk away with soft and natural-appearing augmentation.

Cell assisted fat transfer is a promising treatment for facial rejuvenation and soft tissue augmentation because there are no incisional scars or complications associated with foreign materials.

The cell assisted fat transfer training course will be offered through Global Stem Cells Group affiliate Stem Cell

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email stemcelltraining

About Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

###

To view this press release live online, click here